Next Article in Journal
Proposed Changes to the Reimbursement of Pharmaceuticals and Medical Devices in Poland and Their Impact on Market Access and the Pharmaceutical Industry
Previous Article in Journal
A Tolerability Burden Index in Schizophrenia: Incorporating Patient Perspective in Clinical Trial Adverse Event Reporting
 
 
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Healthcare Resource Use in Schizophrenia, EuroSC Findings

1
Health Economics and Outcomes Research, Creativ-Ceutical, 15 rue du Faubourg Saint Honoré, Paris, France
2
Market Access, Medical & Marketing, Gedeon Richter Plc, Budapest, Hungary
3
Health Economics and Outcomes Research, Creativ-Ceutical, Beijing, China
4
Public Health Department, Aix-Marseille University, Marseille, France
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2017, 5(1), 1372027; https://doi.org/10.1080/20016689.2017.1372027
Submission received: 31 May 2017 / Revised: 1 January 2017 / Accepted: 22 August 2017 / Published: 5 September 2017

Abstract

Background: It is unclear if the burden associated with schizophrenia is affected by the type and severity of patient’s symptoms. Objective: This study aims to quantify healthcare resource use associated with different profiles of schizophrenia symptoms. Study design: Post-hoc analysis of data from a naturalistic follow-up study. Setting: Secondary psychiatric services in France, Germany and the UK. Patients: EuroSC cohort:, representative sample of 1,208 schizophrenia patients. Main outcome measure: We classified patients into eight health states, according to the Lenert classification (HS1–HS8), and estimated 6-month healthcare resource use (outpatient and day clinic visits, and hospitalisations) across the health states. Results: Approximately half of the patients were classed as having mild symptoms (HS1), with around 20% experiencing moderate, predominantly negative symptoms (HS2). The remaining health states were represented by <10% of patients each. Very few patients experienced extremely severe symptoms (HS8). No health state was associated with excess utilisation across all resource types. In terms of outpatient visits, patients were estimated to see a psychiatrist most often (3.01–4.15 visits over 6 months). Hospital admission was needed in 11%(HS1) – 35%(HS8) of patients and inpatient stays were generally prolonged for all health states (39–57 days). The average number of inpatient days was highest for patients in HS8 (18.17 days), followed by patients with severe negative symptoms (HS4; 13.37 days). In other health states characterised by severe symptoms (HS5–HS7), the average number of inpatient days was approximately half of those seen for HS4 (6.09–7.66). Conclusion: While none of the symptom profiles was associated with excess resource usage, hospitalization days were highest for HS with severe, predominantly negative or extremely severe symptoms. Patients with predominantly negative, moderate or severe symptoms appeared to have a high number of psychologist visits – an interesting finding that may reflect a specific therapeutic approach to the treatment of these patients.
Keywords: schizophrenia; resource use; hospitalisation; outpatient visits; negative symptoms; EuroSC schizophrenia; resource use; hospitalisation; outpatient visits; negative symptoms; EuroSC

Share and Cite

MDPI and ACS Style

Millier, A.; Horváth, M.; Ma, F.; Kóczián, K.; Götze, A.; Toumi, M. Healthcare Resource Use in Schizophrenia, EuroSC Findings. J. Mark. Access Health Policy 2017, 5, 1372027. https://doi.org/10.1080/20016689.2017.1372027

AMA Style

Millier A, Horváth M, Ma F, Kóczián K, Götze A, Toumi M. Healthcare Resource Use in Schizophrenia, EuroSC Findings. Journal of Market Access & Health Policy. 2017; 5(1):1372027. https://doi.org/10.1080/20016689.2017.1372027

Chicago/Turabian Style

Millier, A., M. Horváth, F. Ma, K. Kóczián, A. Götze, and M. Toumi. 2017. "Healthcare Resource Use in Schizophrenia, EuroSC Findings" Journal of Market Access & Health Policy 5, no. 1: 1372027. https://doi.org/10.1080/20016689.2017.1372027

APA Style

Millier, A., Horváth, M., Ma, F., Kóczián, K., Götze, A., & Toumi, M. (2017). Healthcare Resource Use in Schizophrenia, EuroSC Findings. Journal of Market Access & Health Policy, 5(1), 1372027. https://doi.org/10.1080/20016689.2017.1372027

Article Metrics

Back to TopTop